In Brief: OIG exclusion authority
This article was originally published in The Gray Sheet
Executive Summary
OIG exclusion authority: Office of Inspector General proposes to expand exclusion authority to "indirect" providers, including manufacturers and distributors of medical devices and other durable medical equipment reimbursable under Medicare and Medicaid, in an advanced notice of proposed rulemaking published in the Sept. 8 Federal Register. As a result of such a change, no payment would be made to any "direct" providers, such as practitioners, suppliers or pharmacies, for products made by an excluded manufacturer. Comments on the ANPRM are due by Nov. 7...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.